Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge

Summary Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy has paved the way to an even greater demand for these molecules. In order to satisfy this growing demand and to increase the...

Full description

Saved in:
Bibliographic Details
Published in:Plant biotechnology journal 2004-03, Vol.2 (2), p.83-100
Main Authors: Gomord, Véronique, Sourrouille, Christophe, Fitchette, Anne-Catherine, Bardor, Muriel, Pagny, Sophie, Lerouge, Patrice, Faye, Loïc
Format: Article
Language:English
Subjects:
antibody
biotechnology
glycosylation
molecular farming
plant-made pharmaceuticals
recombinant protein
transgenic plant
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy has paved the way to an even greater demand for these molecules. In order to satisfy this growing demand and to increase the production capacity, alternative systems based on antibody production in transgenic organisms are being actively explored. In this paper, we focus on transgenic plants as a promising system for the scale‐up and processing of plant‐made pharmaceuticals. In particular, we point out the advantages and limitations induced by glycosylation of plant‐made antibodies for human therapy.
ISSN:1467-7644
1467-7652
DOI:10.1111/j.1467-7652.2004.00062.x